In 1972, the World Health Organization (WHO) Male Task Force concluded that a long-acting gestagen to suppress pituitary gonadotropin secretion, and hence testicular activity, supplemented by androgen replacement therapy, was the way to develop a male contraceptive. But which gestagen, and which androgen, in what dose, and by what route of administration? These questions still remain, 32 years later, although the latest Australian study,1 has shown that three-monthly injections of 300 mg depot medroxyprogesterone acetate and four-monthly implants of 800 mg testosterone give excellent contraceptive protection for one year.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.